Keiko Igaki

Discovery of [<i>cis</i>-3-({(5<i>R</i>)-5-[(7-Fluoro-1,1-dimethyl-2,3-dihydro-1<i>H</i>-inden-5-yl)carbamoyl]-2-methoxy-7,8-dihydro-1,6-naphthyridin-6(5<i>H</i>)-yl}carbonyl)cyclobutyl]acetic Acid (TAK-828F) as a Potent, Selective, and Orally Available Novel Retinoic Acid Receptor-Related Orphan Receptor γt Inverse Agonist

Mitsunori Kono, Atsuko Ochida, Tsuneo Oda et al. · Journal of Medicinal Chemistry · 2018 · 62 citations

Pharmacotherapy, Pharmaceutical Chemistry, Pre-clinical Pharmacology +16

Establishment and validation of a new semi-chronic dextran sulfate sodium-induced model of colitis in mice

Takukyu Sha, Keiko Igaki, Masashi Yamasaki et al. · International Immunopharmacology · 2012 · 34 citations

Inflammation, Allergy, Mucosal Immunology +5

Pharmacological inhibitory profile of TAK-828F, a potent and selective orally available RORγt inverse agonist

Akira Shibata, Keiko Uga, Takayuki Sato et al. · Biochemical Pharmacology · 2018 · 31 citations

Molecular Pharmacology, Pharmacological Inhibitory Profile, Medicine +6

MLN3126, an antagonist of the chemokine receptor CCR9, ameliorates inflammation in a T cell mediated mouse colitis model

Keiko Igaki, Yusaku Komoike, Yoshiki Nakamura et al. · International Immunopharmacology · 2018 · 30 citations

Inflammation, Cytokine, Immune Regulation +10

Synthesis and Biological Activities of 4-Phenyl-5-pyridyl-1,3-thiazole Derivatives as p38 MAP Kinase Inhibitors

Seiji Miwatashi, Yasuyoshi Arikawa, Ken‐ichi Naruo et al. · Chemical and Pharmaceutical Bulletin · 2005 · 24 citations · Full text

Immunology, Biological Activities, Heterocycle Chemistry +16